SEATTLE, Jan. 31 /PRNewswire/ -- Koronis Pharmaceuticals, Inc., a biotechnology company focused on the development of antiviral therapeutics, today announced the appointment of Daniel H. Petree and George R. Painter, Ph.D. to the Company's board of directors.
Mr. Petree is a founder and member of P2 Partners, LLC, a boutique investment bank specializing in life science companies. Prior to forming P2 Partners, Mr. Petree held various executive management positions in the life sciences industry, including President and Chief Operating Officer of Axys Pharmaceuticals and Vice President of Business Development at TSI Corporation. He also served as Vice President in the Health Care Group at the investment bank Montgomery Securities. Mr. Petree currently serves as Director for Cypress BioSciences.
Dr. Painter is president and chief executive officer of Chimerix, a biotechnology company developing orally available antiviral therapeutics. Prior to that, he served as Executive Vice President, Research and Development, at Triangle Pharmaceuticals where he was a member of the founding management team. Dr. Painter has also held positions at Burroughs Wellcome Co., and Glaxo Wellcome Inc. Dr. Painter is a co-inventor of over forty-five patents, six of which have led to approved commercially available drugs or combinations of drugs for the treatment of HIV and hepatitis B. Dr. Painter earned a B.S. in chemistry, an M.S. in physical organic chemistry and a Ph.D. in synthetic chemistry from Emory University.
Koronis Pharmaceuticals, Inc. is a privately held biotechnology company
developing anti-viral therapeutics based on a novel mechanism, Viral Decay
Acceleration (VDA). The Company's lead product candidate, KP-1461 for the
treatment of human immunodeficiency virus (HIV), is currently being
evaluated in a Phase 2 trial. In addition to KP-1461, the Company has
products in development for the treatment of hepatitis C and RSV. For more
information on Koronis, please visit http://www.koronispharma.com.
Rathbun Communications, Inc.
Tel : (206) 769-9219
|SOURCE Koronis Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved